Next-Generation Proteomics of Brain Extracellular Vesicles in Schizophrenia Provide New Clues on the Altered Molecular Connectome.

brain antibodies extracellular vesicles immunoglobulins molecular exchange neuroinflammation psychiatry psychotic spectrum systems biology

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
08 Jan 2024
Historique:
received: 20 12 2023
revised: 30 12 2023
accepted: 05 01 2024
medline: 23 1 2024
pubmed: 23 1 2024
entrez: 23 1 2024
Statut: epublish

Résumé

Extracellular vesicles (EVs) are tiny membranous structures that mediate intercellular communication. The role(s) of these vesicles have been widely investigated in the context of neurological diseases; however, their potential implications in the neuropathology subjacent to human psychiatric disorders remain mostly unknown. Here, by using next-generation discovery-driven proteomics, we investigate the potential role(s) of brain EVs (bEVs) in schizophrenia (SZ) by analyzing these vesicles from the three post-mortem anatomical brain regions: the prefrontal cortex (PFC), hippocampus (HC), and caudate (CAU). The results obtained indicate that bEVs from SZ-affected brains contain region-specific proteins that are associated with abnormal GABAergic and glutamatergic transmission. Similarly, these vesicles from the analyzed regions were implicated in synaptic decay, abnormal brain immunity, neuron structural imbalances, and impaired cell homeostasis. Our findings also provide evidence, for the first time, that networks of molecular exchange (involving the PFC, HC, and CAU) are potentially active and mediated by EVs in non-diseased brains. Additionally, these bEV-mediated networks seem to have become partially reversed and largely disrupted in the brains of subjects affected by SZ. Taken as a whole, these results open the door to the uncovering of new biological markers and therapeutic targets, based on the compositions of bEVs, for the benefit of patients affected by SZ and related psychotic disorders.

Identifiants

pubmed: 38255234
pii: biomedicines12010129
doi: 10.3390/biomedicines12010129
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Instituto de Salud Carlos III
ID : PI22/00443
Organisme : Agencia Estatal de Investigación
ID : PID2020-114885RB-C21
Organisme : Ministerio de Ciencia e Innovación
ID : PRTR-C17.I1
Organisme : Government of Catalonia
ID : EVBRAINTARGET-Y7340-ACPPCCOL007
Organisme : Diputació de Lleida
ID : PIRS22/03
Organisme : Diputació de Lleida
ID : PIRS23/02
Organisme : Agency for Administration of University and Research
ID : AGAUR 21SGR010065
Organisme : Basque Government
ID : IT211/19
Organisme : Basque Government
ID : IT1512/22

Auteurs

Cristina Lorca (C)

Biomedical Research Institute of Lleida Dr. Pifarré Foundation (IRBLLEIDA), Neuroscience Area, +Pec Proteomics Research Group (+PPRG), University Hospital Arnau de Vilanova (HUAV), 80 Av. Rovira Roure, 25198 Lleida, Spain.
Department of Medical Basic Sciences, Biomedical Research Institute of Lleida Dr. Pifarré Foundation (IRBLLEIDA), +Pec Proteomics Research Group (+PPRG), University of Lleida (UdL), 25198 Lleida, Spain.

María Fernández-Rhodes (M)

Biomedical Research Institute of Lleida Dr. Pifarré Foundation (IRBLLEIDA), Neuroscience Area, +Pec Proteomics Research Group (+PPRG), University Hospital Arnau de Vilanova (HUAV), 80 Av. Rovira Roure, 25198 Lleida, Spain.
Department of Medical Basic Sciences, Biomedical Research Institute of Lleida Dr. Pifarré Foundation (IRBLLEIDA), +Pec Proteomics Research Group (+PPRG), University of Lleida (UdL), 25198 Lleida, Spain.

Jose Antonio Sánchez Milán (JA)

Biomedical Research Institute of Lleida Dr. Pifarré Foundation (IRBLLEIDA), Neuroscience Area, +Pec Proteomics Research Group (+PPRG), University Hospital Arnau de Vilanova (HUAV), 80 Av. Rovira Roure, 25198 Lleida, Spain.
Department of Medical Basic Sciences, Biomedical Research Institute of Lleida Dr. Pifarré Foundation (IRBLLEIDA), +Pec Proteomics Research Group (+PPRG), University of Lleida (UdL), 25198 Lleida, Spain.

María Mulet (M)

Biomedical Research Institute of Lleida Dr. Pifarré Foundation (IRBLLEIDA), Neuroscience Area, +Pec Proteomics Research Group (+PPRG), University Hospital Arnau de Vilanova (HUAV), 80 Av. Rovira Roure, 25198 Lleida, Spain.
Department of Medical Basic Sciences, Biomedical Research Institute of Lleida Dr. Pifarré Foundation (IRBLLEIDA), +Pec Proteomics Research Group (+PPRG), University of Lleida (UdL), 25198 Lleida, Spain.

Félix Elortza (F)

Proteomics Platform, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), CIBERehd, Science and Technology Park of Bizkaia, 48160 Derio, Spain.

Alfredo Ramos-Miguel (A)

Department of Pharmacology, University of the Basque Country UPV/EHU, 48940 Leioa, Spain.
Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Centro de Investigación Biomédica en Red en Salud Mental CIBERSAM, Instituto de Salud Carlos III, 43206 Reus, Spain.

Luis F Callado (LF)

Department of Pharmacology, University of the Basque Country UPV/EHU, 48940 Leioa, Spain.
Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Centro de Investigación Biomédica en Red en Salud Mental CIBERSAM, Instituto de Salud Carlos III, 43206 Reus, Spain.

J Javier Meana (JJ)

Department of Pharmacology, University of the Basque Country UPV/EHU, 48940 Leioa, Spain.
Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Centro de Investigación Biomédica en Red en Salud Mental CIBERSAM, Instituto de Salud Carlos III, 43206 Reus, Spain.

Maria Mur (M)

Psychiatry Department, Hospital Universitari Santa Maria, Medicine Department, Universitat de Lleida (UdL), 25198 Lleida, Spain.

Iolanda Batalla (I)

Psychiatry Department, Hospital Universitari Santa Maria, Medicine Department, Universitat de Lleida (UdL), 25198 Lleida, Spain.

Elisabet Vilella (E)

Centro de Investigación Biomédica en Red en Salud Mental CIBERSAM, Instituto de Salud Carlos III, 43206 Reus, Spain.
Hospital Universitari Institut Pere Mata, Institut Investigació Sanitària Pere Virgili (IISPV)-CERCA, Universitat Rovira i Virgili, 43206 Reus, Spain.

Aida Serra (A)

Department of Medical Basic Sciences, Biomedical Research Institute of Lleida Dr. Pifarré Foundation (IRBLLEIDA), +Pec Proteomics Research Group (+PPRG), University of Lleida (UdL), 25198 Lleida, Spain.

Xavier Gallart-Palau (X)

Biomedical Research Institute of Lleida Dr. Pifarré Foundation (IRBLLEIDA), Neuroscience Area, +Pec Proteomics Research Group (+PPRG), University Hospital Arnau de Vilanova (HUAV), 80 Av. Rovira Roure, 25198 Lleida, Spain.
Department of Psychology, University of Lleida (UdL), 25001 Lleida, Spain.

Classifications MeSH